A high yield, intermediate purity factor VIII concentrate derived from heparinized plasma has been developed which can be heat-treated at 60 °C, 68 °C or 80 °C/72 h to permit inactivation of viral contaminants which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC precipitate was adjusted to 25-30 mg/ml protein and pH 6.35 ± 0.1 and incubated for 1 h at 8 °C. After centrifugation to remove the precipitated fibrinogen and fibronectin, a factor VIII-rich supernatant can be recovered which contains > 500 units of VIII : C per liter of starting plasma (Method I product) at a purity of 1.5 U/mg protein. Adjusted to 50 mM glycine and pH 6.8, the product can be lyophilized and heat-treated at 60 °C/72 h without a significant loss of VIII :C activity. However, at 68 °C or 80 °C/72 h, temperatures now reported to be more effective in viral inactivation, the recoveries were reduced to 68 and 33% respectively. Significantly improved recoveries after heat-treatment (HT) at 68 °C or 80 °C/72 h were achieved if the 8 °C supernatant product was prepared by a modified procedure (Method II). This further reduces the fibrinogen content of the product while maintaining VIII : C yields > 500 U/l at a purity of 1.9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose (pH 6.8), lyophilized and heat treated at 60 °C, 68 °C or 80 °C/72 h, the VIII :C recoveries of Method II product were 88-100%, 79-84% and 80-83% of pre-HT levels respectively. The yield of VIII : C was > 400 U/l at a purity of 1.6-1.4 U/mg at 1-2% (w/v) sucrose even after the severe heat-treatment at 80 °C. In addition, the von Willebrand factor multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.
References
1
Rock GA,
Cruickshank WH,
Tackaberry ES,
Palmer DS.
Improved yields of factor VIII from heparinized plasma. Vox Sang 1979; 36: 294-300
3
Rock G,
Smiley RK,
Tittley P,
Palmer DS.
In vivo effectiveness of a high yield Factor VIII concentrate prepared in a blood bank. New Engl J Med 1984; 311: 310-3
9
Horowitz B,
Lippin A,
Chang MY,
Shulman RW,
Vandersande J,
Stryker MH,
Woods KR.
Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate. Transfusion 1984; 24: 357-62
11
Brcckenridge RT,
Ratnoff OD.
Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: With notes on an assay for antihemophilic factor. Blood 1962; 20: 137-47
12
Rock GA,
Cruickshank WH,
Tackaberry ES,
Ganz PR,
Palmer DS.
Stability of VIII: C in plasma: The dependence on protease activity and calcium. Thromb Res 1983; 29: 521-35
1
Rock GA.
FVIII: C one-stage assay of plasma containing heparin. In: Development Systems for Efficient Separation of Factor VIII from Human Fresh-frozen Plasma.
Lane RS,
Rock GA,
Smit Sibinga CTh.
(eds). Proceedings of a Workshop on Factor VIII;; Groningen, The Netherlands: 23.11.1981. pp 26-30
14
Zimmerman TS,
de la Pointe LI,
Edgington TS.
Interaction of Factor VIII antigen in hemophilic plasmas with human antibodies to Factor VIII. J Clin Invest 1977; 59: 984-9
17
Palmer DS,
Harris AS,
Tittley P,
Rock G.
The effectiveness, specificity and safety of intranasal DDAVP treatment of normal blood donors. Haemostasis 1988; 18: 187-96
23
Rock GA,
Tackaberry ES,
Palmer DS.
Factors affecting the relative distribution of high and low molecular weight forms of Factor VIII. Thromb Res 1979; 14: 573-87
25
Melief CJ M,
Goudsmits J.
Transmission of lymphotropic retroviruses (HTLV-I and LAV/HTLV-III) by blood transfusion and blood products. Vox Sang 1986; 50: 1-11
28
Van den Berg W,
Ten Cate JW,
Breederveld C,
Goudsmit J.
Seroconversion to HTLV-VIII in a haemophiliac given heat-treated factor VIII concentrate. Lancet 1986; i: 803-4
29
White GC,
Mathews TJ,
Weinhold KJ,
Haynes BF,
Le Roy Cromartie H,
McMillan CW,
Bolgnesi DP.
HTLV III seroconversion associated with heat-treated factor VIII concentrate. Lancet 1986; i: 611-2
31
Hilfenhaus J,
Weidmann E.
Pasteurization as an efficient method to inactivate blood borne viruses in Factor VIII concentrates. Drug Res 1986; 36: 621-5
33
Thomas KB,
McGrath KM,
Taylor M,
Young IF,
Herrington RW,
Schiff P.
Effect of virucidal heat-treatment on proteins in human factor VIII concentrates. Transfusion 1988; 28: 8-13
37
Edwards CA,
Piet MP J,
Chin S,
Horowitz B.
Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987; 52: 53-9
38
Prince AM,
Horowitz B,
Brotman B,
Huima T,
Richardson L,
van den Ende MC.
Inactivation of hepatitis B and Hutchison strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang 1984; 46: 36-43
39
Prince AM,
Horowitz B,
Brotman B.
Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl) phosphate and sodium cholate. Lancet 1986; i: 706-10
40
Horowitz B,
Wiebe ME,
Lippin A,
Stryker MH.
Inactivation of virus in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl) phosphate detergent conditions. Transfusion 1985; 25: 516-22
42
Fukui H,
Nishino M,
Terada S,
Nishikuba T,
Yoshioka A,
Kinoshita S,
Niimoni K,
Yoshioka K.
Hemostatic effect of a heat-treated Factor VIII concentrate (Haemate P) in von Willebrand’s Disease. Blut 1988; 56: 171-8
43
Blatt PM,
Brinkhous KM,
Culp HR,
Krauss JS,
Robert HR.
Antihemophilic factor concentrate therapy in von Willebrand’s Disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 1976; 236: 2770-2
45
Mazurier C,
de Romeuf C,
Parquet-Gernez A,
Jorieux S,
Goudeman M.
In vitro and in vivo evaluation of Factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Vox Sang 1987; 52: 265-71
47
Newman J,
Johnson AJ,
Karpatkin MH,
Puszkin S.
Methods for the preparation of clinically effective intermediate and high-purity Factor-VIII concentrate. Br J Haematol 1971; 21: 1-20
